Imprimis NJOF, LLC is recalling a specific lot of Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic Suspension because there is no assurance that the product remains sterile. The affected batch contains 4,280 boxes distributed nationwide in the United States. This recall was initiated on May 14, 2024. Read more at govinfonow.com/recall/32669-imprimis-recalls-prednisolone-moxifloxacin-bromfenac-eye-drops-due-to-sterility.
“Imprimis Recalls Prednisolone-Moxifloxacin-Bromfenac Eye Drops Due to Sterility Risk.” GovInfoNow, updated October 9, 2026. https://govinfonow.com/recall/32669-imprimis-recalls-prednisolone-moxifloxacin-bromfenac-eye-drops-due-to-sterility. Based on FDA recall #D-0548-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0548-2024%22&limit=1).
The Food and Drug Administration announced on May 14, 2024, that Imprimis NJOF, LLC is recalling Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic Suspension due to a lack of assurance of sterility. The agency issued the recall for Class II violations involving compounded eye drops distributed nationwide.
The recall addresses a lack of assurance of sterility in the Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic Suspension. The FDA classified this as a Class II recall, indicating a temporary or reversible health hazard.
Context
GovInfoNow's records show Imprimis NJOF, LLC has 13 other recalls on record since December 17, 2020. Recent brand recalls include an Imprimis Tri-Moxi+ Intraocular Injection recall for glass particles risk on December 18, 2025, and a Klarity-C Drops recall for subpotent drug risk on October 20, 2025. Other recent recalls of similar products include Clear Eyes Eye Drops recalled for sterility risk on July 29, 2026, Geri-Care Eye Drops recalled for sterility risk on March 25, 2026, and Thea Pharma Similasan Eye Drops recalled for sterility risk from FDA inspection on April 23, 2026.
How to tell if you have this one
Check your medication bottle for NDC 71384-310-05 and Lot number 23NOV018. The expiration date on the label is 6/17/24. The product is a Sterile Ophthalmic Suspension containing Prednisolone 1%, Moxifloxacin 0.5%, and Bromfenac 0.075% in a 5mL quantity.
Brand
Imprimis NJOF
Category
Drug
Based on the official FDA remedy
What to do — step by step
Contact Your Pharmacist
Reach out to the pharmacy where you filled your prescription to verify if your specific lot is part of this recall.
Do Not Use Affected Product
If you have the product with Lot 23NOV018, do not use it until you receive further instructions from your healthcare provider or pharmacist.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “US Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 36 days after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0548-2024 (May 14, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0548-2024 to see it in context.
Plain-language summary written by qwen3.6:35b-a3b on October 9, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.